Tekla Capital Management LLC Affimed N.V. Transaction History

Tekla Capital Management LLC

$2.53 Billion
Q2 2023

A detailed history of Tekla Capital Management LLC transactions in Affimed N.V. stock. As of the latest transaction made, Tekla Capital Management LLC holds 586,038 shares of AFMD stock, worth $3.19 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

586,038

Previous 586,038 -0.0%

Holding current value

$3.19 Million

Previous $439,000 20.05%

% of portfolio

0.01%

Previous 0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $1.79 Million - $2.42 Million	-322,698 Reduced 35.51%	586,038 $3.62 Million
Q2 2021 Aug 13, 2021	BUY	$7.78 - $11.4 $4.83 Million - $7.08 Million	620,717 Added 215.51%	908,736 $7.72 Million
Q1 2021 May 14, 2021	BUY	$5.12 - $8.48 $102,400 - $169,600	20,000 Added 7.46%	288,019 $2.28 Million
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $846,940 - $1.88 Million	268,019 New	268,019 $1.56 Million
Q3 2019 Nov 13, 2019	SELL	$2.67 - $3.65 $678,180 - $927,100	-254,000 Closed	0 $0

Q3 2018 Nov 13, 2018	SELL	$1.45 - $6.15 $1.99 Million - $8.43 Million	-1,370,792 Reduced 84.37%	254,000 $1.11 Million
Q2 2018 Aug 13, 2018	SELL	$1.65 - $2.5 $297,877 - $451,330	-180,532 Reduced 10.0%	1,624,792 $2.68 Million
Q1 2018 May 14, 2018	BUY	$1.25 - $2.65 $500,000 - $1.06 Million	400,000 Added 28.46%	1,805,324 $3.34 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,405,324	1,405,324 $2.88 Million

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.1M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $814M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Account

Tekla Capital Management LLC Affimed N.V. Transaction History